Previous 10 | Next 10 |
Summary Merck has seen very strong growth so far this year, even if we strip out the pandemic related contribution. Strong growth has resulted in an uptick in the valuation multiple, all while multiples in the market at large are compressing amidst rising rates. I still like t...
Summary Merck has proven to be a resilient healthcare business that has provided growth, while the share price hasn't moved all that much. This year that has changed, and Merck shares are rising above peers with positive returns YTD. The Merck dividend is attractive and should...
Organon (NYSE: OGN), a global women’s healthcare company will release its third quarter 2022 financial results on November 3, 2022, prior to the company’s webcast and conference call scheduled for 8:30 a.m. EDT. Interested parties may access the live call via webcast o...
Summary In the third quarter of 2022, the Miller Income Strategy returned -7.34% (net of fees) versus a -0.68% return for the ICE BofA US High Yield Index. While the Fed is hiking the cost of money, the lower bound of the Federal funds target rate at the time of this writing is 3....
The S&P 500 notched a new closing low for 2022 as interest rates surged and turmoil rocked global currencies. The Dow Jones Industrials kept on their negative trend, losing 327.76 points to 29,262.65. The S&P 500 fell 38.19 points, or 1% to 3,655.04. The NASDAQ Composite...
Organon Canada reinforces the need to raise awareness and access for contraception methods with nearly half of pregnancies unplanned Canada NewsWire On World Contraception Day, Organon wants to help tackle the global issue of unintended pregnancies by helping ensure wo...
Summary A high level of restructuring is occurring with the Healthcare industry’s largest constituents. Most restructuring is taking the form of splits or spin-offs, but not all incidences look beneficial. This article will summarize coming transactions and provide comm...
The shares of Organon & Co. ( NYSE: OGN ) traded higher in the morning hours Tuesday after Piper Sandler upgraded the Merck ( MRK ) spinoff, citing less than expected sales decline in the company’s Established Brands (EB) division. However, analysts David Amse...
Summary Organon has seen a real struggle in its first year on its own as a publicly listed business. Lack of growth was anticipated, yet the extent of margin pressure has been unexpected. With net debt flattish, leverage ratios have only increased, creating few triggers in the...
Development-stage biotech Oragenics, Inc. ( NYSE: OGN ) announced initial data on Wednesday from an ongoing Good Laboratory Practice (GLP) toxicology study for NT-CoV2-1, an intranasal COVID-19 vaccine candidate. The data, generated from a rabbit model, indicate a safety p...
News, Short Squeeze, Breakout and More Instantly...
VANCOUVER, BC / ACCESSWIRE / July 24, 2024 / (TSXV:OGN)(OTCQX:OGNRF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to announce updates for its partner funded exploration stage projects and royalties. Highlights Estimated 30,000 metres of drilling in seven planned or comp...
Company estimates $15 million of milestone expense in the second quarter Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, will release its second quarter 2024 financial results on August 6, 2024, prior to the company’s webcast and conference...
2024-06-08 06:50:00 ET Not all dividend stocks are equal. Some are safer than others. Some have much higher dividend yields than others. When a stock offers both advantages, it's usually a keeper. Three Motley Fool contributors have found stocks with mouthwatering dividends that you...